Your browser is no longer supported. Please, upgrade your browser.
Settings
VBIV VBI Vaccines Inc. daily Stock Chart
VBIV [NASD]
VBI Vaccines Inc.
Index- P/E- EPS (ttm)-0.76 Insider Own12.00% Shs Outstand178.26M Perf Week6.79%
Market Cap95.94M Forward P/E- EPS next Y-0.77 Insider Trans104.88% Shs Float57.60M Perf Month6.57%
Income- PEG- EPS next Q-0.22 Inst Own55.58% Short Float6.09% Perf Quarter-32.88%
Sales3.94M P/S24.33 EPS this Y0.00% Inst Trans- Short Ratio1.85 Perf Half Y-73.09%
Book/sh0.78 P/B0.69 EPS next Y12.50% ROA- Target Price8.25 Perf Year-74.61%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range0.47 - 2.39 Perf YTD-66.36%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-76.76% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low19.30% ATR0.05
Employees108 Current Ratio- Sales Q/Q173.50% Oper. Margin- RSI (14)51.83 Volatility5.50% 7.59%
OptionableYes Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume1.07 Prev Close0.54
ShortableYes LT Debt/Eq- EarningsNov 08 Payout- Avg Volume1.89M Price0.56
Recom1.50 SMA206.58% SMA50-5.27% SMA200-59.09% Volume1,510,058 Change3.19%
Jan-16-19Initiated Oppenheimer Outperform $9
Nov-01-17Initiated Canaccord Genuity Buy $10
Oct-10-16Initiated Laidlaw Buy $6
Jul-26-16Initiated Ladenburg Thalmann Buy
May-07-15Initiated Noble Financial Buy $7
Oct-22-19 08:00AM  VBI Vaccines Announces Late-Breaker Poster Presentation at The Liver Meeting® 2019 Business Wire
Oct-14-19 08:36AM  The Market Timing Secrets No One Talks About - October 14, 2019 Zacks
Oct-06-19 08:22PM  Weekly CFO Buys Highlight GuruFocus.com
Oct-02-19 08:00AM  VBI Vaccines Announces Late-Breaker Oral Presentation at IDWeek 2019 Business Wire +10.90%
Oct-01-19 08:10AM  The Daily Biotech Pulse: Safety Scare For Anaptys' Psoriasis Drug, NewLink Genetics To Merge With Lumos, Insider Buy Props Up VBI Vaccines Benzinga
Sep-26-19 08:00AM  VBI Vaccines Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares Business Wire -7.33%
Sep-24-19 09:04AM  The Keys to Successfully Timing the Markets - September 24, 2019 Zacks
Sep-19-19 09:00AM  VBI Vaccines Announces Pricing of $35 Million Public Offering Business Wire -26.86%
Sep-18-19 04:01PM  VBI Vaccines Announces Proposed Public Offering of Common Shares Business Wire -6.75%
Sep-10-19 07:00AM  VBI Vaccines Announces Phase 2a Clinical Evaluation of VBI-1901 Cancer Vaccine Candidate in Combination with GSKs AS01B Adjuvant System in Recurrent Glioblastoma Patients Business Wire +10.43%
Sep-04-19 08:58AM  The Keys to Successfully Timing the Markets - September 04, 2019 Zacks
Aug-15-19 09:57AM  The Keys to Successful Timing the Markets - August 15, 2019 Zacks
Aug-09-19 09:15AM  VBI Vaccines, Inc. (VBIV) Reports Q2 Loss, Tops Revenue Estimates Zacks
08:00AM  VBI Vaccines Announces Second Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire
Aug-05-19 08:00AM  VBI Vaccines to Present at the Canaccord Genuity 39th Annual Growth Conference GlobeNewswire
Jul-29-19 08:00AM  VBI Vaccines Announces Dosing of First Recurrent GBM Patient in Part B of Ongoing Phase 1/2a Study of VBI-1901 GlobeNewswire
Jul-18-19 10:32AM  Will VBI Vaccines, Inc. (VBIV) Report Negative Q2 Earnings? What You Should Know Zacks
09:00AM  VBI Vaccines, Inc. (VBIV) Upgraded to Strong Buy: Here's Why Zacks
Jul-01-19 08:00AM  VBI Vaccines Added to Russell 2000® and Russell 3000® Indexes GlobeNewswire -10.26%
Jun-20-19 08:00AM  VBI Vaccines to Present at the BMO Capital Markets 2019 Prescriptions for Success Healthcare Conference GlobeNewswire +20.59%
Jun-19-19 03:15PM  Vbi Vaccines Inc (VBIV) CEO, President Jeff Baxter Bought $105,120 of Shares GuruFocus.com +17.71%
Jun-17-19 06:33AM  UPDATE 2-VBI's shares plunge after hep B vaccine fails secondary goal in late-stage trial Reuters -65.61%
06:09AM  VBI hepatitis B vaccine meets main goals in late-stage trial Reuters
06:00AM  VBI Vaccines Announces Positive Top-Line Results from PROTECT, a Pivotal Phase 3 Study of Sci-B-Vac® GlobeNewswire
Jun-16-19 12:00PM  VBI Vaccines to Host Conference Call Tomorrow to Review PROTECT Phase 3 Clinical Data for Sci-B-Vac® GlobeNewswire
Jun-13-19 05:00PM  VBI Vaccines Announces Results of Annual General Meeting GlobeNewswire
Jun-06-19 04:22AM  VBI Vaccines Sees Hammer Chart Pattern: Time to Buy? Zacks
Jun-04-19 08:00AM  VBI Vaccines Reports Data from Part A of the Ongoing Phase 1/2a Study of VBI-1901 in Recurrent Glioblastoma (GBM) Patients at ASCO 2019 GlobeNewswire
May-06-19 09:00AM  All You Need to Know About VBI Vaccines, Inc. (VBIV) Rating Upgrade to Buy Zacks
May-01-19 01:16PM  VBI Vaccines, Inc. (VBIV) Reports Q1 Loss, Tops Revenue Estimates Zacks
08:00AM  VBI Vaccines Announces First Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire
Apr-30-19 10:32AM  VBI Vaccines, Inc. (VBIV) May Report Negative Earnings: Know the Trend Ahead of Q1 Release Zacks
Apr-23-19 08:00AM  VBI Vaccines Provides Update on GBM Program and Announces Upcoming Conference Call GlobeNewswire
Apr-18-19 07:26AM  5 things to know about Hookipa Pharma ahead of its IPO MarketWatch
Apr-17-19 08:00AM  VBI Vaccines Appoints Dr. Vlad Popovic as Vice President of Clinical Development and Medical Affairs GlobeNewswire
Apr-11-19 04:05PM  VBI Vaccines Appoints Joanne Cordeiro to Board of Directors GlobeNewswire
Apr-03-19 08:00AM  VBI Vaccines Announces Poster Presentation at the 7th International Congenital CMV Conference & 17th International CMV Workshop GlobeNewswire
Mar-18-19 08:00AM  VBI Vaccines to Present at the Oppenheimer 29th Annual Healthcare Conference GlobeNewswire
Feb-25-19 08:00AM  VBI Vaccines Provides Corporate Update, Outlook for 2019, and Year-End 2018 Financial Results GlobeNewswire
Feb-07-19 08:00AM  VBI Vaccines Announces Third Positive DSMB Review in Phase 1/2a Study of VBI-1901 in Recurrent GBM Patients GlobeNewswire +9.83%
Jan-16-19 08:00AM  VBI Vaccines Appoints Blaine McKee to Board of Directors GlobeNewswire +11.30%
Dec-20-18 08:00AM  VBI Vaccines Announces Phase 2 Clinical Study Design of its Prophylactic CMV Vaccine Candidate GlobeNewswire
Dec-18-18 08:00AM  VBI Vaccines Announces Closing of Public Offering of Common Stock and Partial Exercise of Underwriters Option to Purchase Additional Shares for Aggregate Gross Proceeds of $42.9 Million GlobeNewswire
Dec-13-18 09:05AM  VBI Vaccines Announces Pricing of $37.5 Million Public Offering GlobeNewswire -15.66%
Dec-12-18 04:01PM  VBI Vaccines Announces Proposed Public Offering of Common Shares GlobeNewswire +7.10%
Dec-06-18 08:00AM  VBI Vaccines Enters into License and Collaboration Agreement with Brii Biosciences for up to $129 Million plus Royalties to Develop a Functional Cure for Hepatitis B GlobeNewswire +6.33%
Nov-16-18 08:08AM  The Daily Biotech Pulse: Mallinckrodt FDA Verdict, European Cheer For Bristol-Myers Squibb, Morphosys Clinches Licensing Deal Benzinga
Nov-09-18 07:00AM  VBI Vaccines Announces Third Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire -5.53%
Oct-25-18 08:10AM  Research Report Identifies Sorrento Therapeutics, Hurco Companies, Veritiv, Park Electrochemical, VBI Vaccines, and PennantPark Floating Rate Capital with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire -8.63%
Oct-24-18 08:00AM  VBI Vaccines to Present Initial Data for VBI-1901 in Recurrent Glioblastoma (GBM) Patients at the 2018 Annual Meeting of the Society for Neuro-Oncology (SNO) GlobeNewswire
Oct-16-18 08:00AM  VBI Vaccines Completes Vaccination in PROTECT Phase 3 Clinical Study for Sci-B-Vac® Hepatitis B Vaccine GlobeNewswire
Oct-02-18 08:00AM  VBI Vaccines Late-Breaker Cytomegalovirus Abstract Chosen for Oral Presentation at IDWeek 2018 GlobeNewswire
Sep-27-18 08:00AM  VBI Vaccines to Present at the Ladenburg Thalmann 2018 Healthcare Conference GlobeNewswire +6.03%
Sep-26-18 08:00AM  VBI Vaccines Announces Formation of New Scientific and Clinical Advisory Boards GlobeNewswire
Sep-25-18 08:00AM  VBI Vaccines Announces Second Positive DSMB Review in Phase 1/2a Study of VBI-1901 in Recurrent Glioblastoma (GBM) Patients GlobeNewswire
Sep-16-18 01:00AM  VBI Vaccines Responds to Unfounded Allegations in Globes Article GlobeNewswire
Aug-15-18 08:00AM  VBI Vaccines Appoints Christopher McNulty as Chief Financial Officer and Head of Business Development GlobeNewswire
Aug-06-18 04:15PM  VBI Vaccines to Present at the Canaccord Genuity 38th Annual Growth Conference GlobeNewswire -6.28%
Jul-31-18 07:40AM  Report: Developing Opportunities within Amicus Therapeutics, Interpace Diagnostics Group, The Progressive, State Street, Alphabet, and VBI Vaccines Future Expectations, Projections Moving into 2018 GlobeNewswire
Jul-26-18 07:00AM  VBI Vaccines Announces Second Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
Jul-09-18 08:00AM  VBI Vaccines to Participate in the 2018 Oppenheimer Boston Oncology Insight Summit GlobeNewswire
Jun-19-18 08:00AM  VBI Vaccines to Present at 2018 JMP Securities Life Sciences Conference GlobeNewswire
May-25-18 04:15PM  VBI Vaccines Announces Results of Annual General Meeting GlobeNewswire
May-22-18 01:05PM  Well Leveraged: VBI Vaccines Outlines Clinical Trial Progress GlobeNewswire
May-14-18 07:20AM  Wired News VBI Vaccines Reports Positive Data from Final Phase-1 Study for Preventative CMV Vaccine ACCESSWIRE +6.71%
May-10-18 07:30AM  VBI Vaccines Announces Positive Final Phase 1 Study Results of Preventative CMV Vaccine GlobeNewswire +6.14%
May-01-18 08:00AM  VBI Vaccines Announces First Quarter 2018 Financial Results and Provides Corporate Update GlobeNewswire
Apr-23-18 07:30AM  Blog Exposure - VBI Vaccines Announced Dosing of Last Patient in PROTECT Phase-3 Clinical Study for Sci-B-Vac® Hepatitis B Vaccine ACCESSWIRE
Apr-19-18 08:00AM  VBI Vaccines Announces Completion of Enrollment in PROTECT Phase 3 Clinical Study for Sci-B-Vac® Hepatitis B Vaccine GlobeNewswire
Apr-17-18 08:00AM  VBI Vaccines Announces Positive DSMB Review in Phase 1/2a Study of VBI-1901 in Recurrent Glioblastoma (GBM) Patients GlobeNewswire
Mar-15-18 05:00PM  ICYMI: Penny Stocks, Energy ETF, AR And VR Devices Benzinga
Mar-12-18 04:15PM  VBI Vaccines Announces Voluntary Delisting from the Toronto Stock Exchange GlobeNewswire
Feb-26-18 08:20AM  Consolidated Research: 2018 Summary Expectations for Progress Software, Cracker Barrel Old Country Store, Natural Grocers by Vitamin Cottage, VBI Vaccines, Ardelyx, and CytomX Therapeutics Fundamental Analysis, Key Performance Indications GlobeNewswire
Jan-26-18 04:15PM  VBI Vaccines Announces Changes to its Board of Directors GlobeNewswire
Jan-17-18 08:00AM  VBI Vaccines Announces Dosing of First GBM Patient in Phase 1/2a Clinical Study of VBI-1901 GlobeNewswire
Dec-26-17 12:17PM  ETFs with exposure to VBI Vaccines, Inc. : December 26, 2017 Capital Cube
Dec-25-17 09:24AM  VBI Vaccines, Inc. :VBIV-US: Earnings Analysis: Q3, 2017 By the Numbers : December 25, 2017 Capital Cube
Dec-19-17 08:00AM  VBI Vaccines Announces Initiation of Phase 3 Clinical Program for Sci-B-Vac® Hepatitis B Vaccine GlobeNewswire
Dec-12-17 08:00AM  VBI Vaccines to Present at the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference GlobeNewswire
Nov-15-17 01:04PM  VBI Vaccines Could Nearly Triple In Value On New Drug Launches, According To BMO Benzinga
Nov-13-17 01:00PM  VBI: Multiple Platforms Yield a Portfolio of Vaccines Zacks Small Cap Research
Nov-10-17 08:00AM  VBI Vaccines to Present New Preclinical Data for its GBM Immunotherapy, VBI-1901, at SITC 2017 GlobeNewswire
Nov-02-17 08:00AM  VBI Vaccines Strengthens Board of Directors with Appointment of Ran Nussbaum GlobeNewswire
Oct-31-17 08:30AM  VBI Vaccines Announces Closing of Public Offering and Concurrent Registered Direct Offering of Common Shares GlobeNewswire
Oct-30-17 08:00AM  VBI Vaccines Announces Full Exercise of Underwriters Option to Purchase Additional Shares and Upsized Registered Direct Offering for Aggregate Proceeds of $71.9 Million GlobeNewswire
Oct-26-17 10:53AM  ETFs with exposure to VBI Vaccines, Inc. : October 26, 2017 Capital Cube
09:29AM  VBI Vaccines Prices Concurrent Public Offering and Registered Direct Offering for Aggregate Proceeds of $63.5 Million GlobeNewswire
Oct-25-17 04:01PM  VBI Vaccines Announces Proposed Concurrent Public Offering and Registered Direct Offering of Common Shares GlobeNewswire
Oct-17-17 08:00AM  VBI Vaccines Hepatitis B Data Selected as Presidential Poster of Distinction at The Liver Meeting(R) 2017 Marketwired
Oct-11-17 08:00AM  VBI Vaccines to Present at The World Vaccine Congress Europe 2017 in Barcelona Marketwired
Sep-12-17 08:00AM  VBI Vaccines to Present at September 2017 Investor Conferences Marketwired
Aug-30-17 08:00AM  VBI Vaccines Announces FDA Acceptance of Investigational New Drug Application for Sci-B-Vac(R) Phase 3 Clinical Program Marketwired
Aug-28-17 07:05PM  ETFs with exposure to VBI Vaccines, Inc. : August 28, 2017 Capital Cube
08:30AM  VBI Vaccines to Present New Preclinical Data for its GBM Immunotherapy, VBI-1901, at The Immuno-Oncology Summit Marketwired
Aug-24-17 10:54AM  VBI Vaccines, Inc. :VBIV-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017 Capital Cube
Aug-18-17 06:29PM  ETFs with exposure to VBI Vaccines, Inc. : August 18, 2017 Capital Cube
Aug-15-17 08:30AM  VBI Vaccines Announces FDA Acceptance of Investigational New Drug Application for VBI-1901 to Treat Glioblastoma Multiforme Marketwired
Aug-07-17 11:04AM  VBI Vaccines, Inc. :VBIV-US: Earnings Analysis: Q1, 2017 By the Numbers : August 7, 2017 Capital Cube
Jul-27-17 07:30AM  VBI Vaccines Announces Positive Interim Data from Phase 1 Study of Preventative CMV Vaccine Marketwired
Jul-11-17 04:05PM  VBI Vaccines Announces Phase 3 Clinical Program for Sci-B-Vac(TM) Hepatitis B Vaccine Marketwired
VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a prophylactic hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the structure of the target virus. It is also developing cytomegalovirus vaccine candidate for infectious disease; and glioblastoma multiforme vaccine candidate for immuno-oncology. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. The company is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Diaz-Mitoma FranciscoChief Medical OfficerOct 04Buy0.5040,00020,000117,500Oct 07 11:35 AM
Beattie NellChief Business OfficerOct 01Buy0.4810,0004,82260,000Oct 01 12:39 PM
McNulty ChristopherCFO and Head of BDOct 01Buy0.4712,0005,67637,000Oct 01 12:39 PM
Diaz-Mitoma FranciscoChief Medical OfficerSep 30Buy0.5014,5007,25014,500Oct 07 11:35 AM
Baxter JeffCEO, PresidentSep 30Buy0.50150,00075,450608,255Sep 30 04:22 PM
PERCEPTIVE ADVISORS LLC10% OwnerSep 23Buy0.5020,000,00010,000,00045,951,556Sep 24 06:30 PM
Diaz-Mitoma FranciscoChief Medical OfficerJun 27Buy1.078,0008,56077,500Jul 01 06:10 AM
Diaz-Mitoma FranciscoChief Medical OfficerJun 20Buy0.8752,00045,18069,500Jun 20 03:59 PM
Beattie NellChief Business OfficerJun 19Buy0.748,0005,88650,000Jun 19 12:20 PM
Baxter JeffCEO, PresidentJun 19Buy0.73144,000105,336458,255Jun 19 12:17 PM
PERCEPTIVE ADVISORS LLC10% OwnerJun 18Buy0.651,000,000650,00025,951,556Jun 20 10:19 AM
PERCEPTIVE ADVISORS LLC10% OwnerJun 17Buy0.621,000,000618,00024,951,556Jun 18 11:10 AM
Kariv TomerDirectorDec 17Buy1.401,428,5711,999,9991,744,969Dec 18 12:10 PM
PERCEPTIVE ADVISORS LLC10% OwnerDec 13Buy1.4014,285,71420,000,00023,631,439Dec 17 09:02 AM